<DOC>
	<DOCNO>NCT02022163</DOCNO>
	<brief_summary>A phase I trial conduct single centre , observer-blind , randomize , dose-ranging , placebo-controlled study evaluate safety , tolerability , immunogenicity 2 intramuscular injection plant-based H7 VLP Influenza Vaccine administer healthy adult , 18-60 year age .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Plant-made H7 Virus-like Particle ( VLP ) Influenza Vaccine Adults .</brief_title>
	<detailed_description>This study consist dose-ranging one hundred ( 100 ) subject randomize parallel 1:1:1:1:1 ratio five ( 5 ) group 20 subject receive one intramuscular injection Days 0 21 either low , medium high dose H7 VLP vaccine mix Alhydrogel® 0.4 % ( 0.5 mg Aluminum per dose ) high dose H7 VLP alone placebo preparation ( 100 millimolar ( mM ) phosphate buffer + 150 mM sodium chloride ( NaCl ) + 0.01 % Tween 80 ) . Twenty-one ( 21 ) day immunization , key safety immunogenicity data collect analysed . All subject follow safety Day 228 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>RNA Virus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Male female adult , 18 60 year age , inclusive Healthy judge Investigator designee determine medical history , complete general history/symptomdirected physical examination , vital sign , screen laboratory , medical history conduct 30 day prior study vaccine administration BMI ≥18 ≤32 Comprehension study requirement , express availability require study period , ability attend schedule visit Accessible phone consistent basis Give his/her consent participate study ( sign ICF ) . In opinion Investigator , competence willingness provide write , informed consent participation reading inform consent form . The subject must adequate opportunity discus study Investigator qualify designee If female , negative pregnancy test result prior first immunization Female childbearing potential ( except subject monogamous sex relationship ) , must use effective birth control 28 day prior immunization must agree continue employ adequate birth control measure Day 0 ( first immunization ) least 60 day postsecond immunization must plan become pregnant Day 0 ( first immunization ) least 60 day postsecond immunization . Highly effective birth control include hormonal contraceptive ( e.g. , injectable , topical [ patch ] , estrogenic vaginal ring , etc . ) , intrauterine device ( IUD ) , abstinence ( confirmed Investigator ) , male condom plus spermicide . Abstinent subject ask method ( ) would use , circumstance change , subject without welldefined plan exclude Presence significant acute chronic , uncontrolled medical neuropsychiatric illness . `` Uncontrolled '' define Requiring new medical surgical treatment within one month prior study vaccine administration Requiring change medication dosage one month prior study vaccine administration due uncontrolled symptom drug toxicity ( elective dosage adjustment stable subject acceptable ) Hospitalization event fulfil definition serious adverse event within one month prior study vaccine administration Any medical neuropsychiatric condition history excessive alcohol use drug abuse , Investigator 's opinion , would render subject incompetent provide inform consent unable provide valid safety observation report Any confirm suspected immunosuppressive condition immunodeficiency include history human immunodeficiency virus ( HIV ) infection , Hepatitis B C , presence lymphoproliferative disease Presence febrile illness , oral temperature &gt; 38.0˚C within 24 hour prior immunization . Such subject may reevaluate enrolment resolution illness History autoimmune disease Administration vaccine ( include influenza vaccine ) within 30 day prior study enrolment plan administration within period vaccination blood sample Day 42 within 30 day prior blood sample Day 228 . Immunization emergency basis tetanus diphtheria toxoid adsorb adult use ( Td ) allow provide vaccine administer within two week prior study vaccine administration . Receipt emergency immunization ( e.g. , rabies ) result casebycase review medical monitor continue participation Administration adjuvanted investigational influenza vaccine 'simple ' seasonal Trivalent Inactivated Vaccine ( TIV ) Quadrivalent Inactivated Vaccine ( QIV ) within 1 year prior study enrolment plan administration prior end trial ( Day 228 ) Use investigational nonregistered product within 30 day prior study enrolment plan use study period . Subjects may participate investigational market drug study participate study Treatment systemic glucocorticoid dose exceed 10 mg prednisone per day , equivalent 7 consecutive day 10 day total , within one month study vaccine administration , cytotoxic immunosuppressant drug , globulin preparation within 3 month vaccination . Low dos nasal inhaled glucocorticoid generally allow Use high dose inhale steroid oral parenteral high dose steroid medication . Nasal steroid allow Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin [ ≤ 325 mg/day ( 1 regular adult aspirin ) ≤ 81 mg/day ( 1 baby aspirin ) ] , without clinically apparent bleeding tendency eligible History previous H7N9 vaccination history exposure H7N9 virus . Any subject enrol previous H7N9 study ( except one receive placebo ) would eligible Are high risk contract H7N9 influenza infection ( e.g . poultry worker ) History allergy constituent H7 VLP ( H7N9 ) study vaccine , Alhydrogel® ( aluminum hydroxide ) , phosphatebuffered saline ( PBS ) ( use placebo ) History severe allergic reaction ( include anaphylaxis ) food , medication bee sting previous severe asthma . History tobacco allergy Continuous use antihistamine last 4 week prior first immunization use antihistamines 48 hour prior study immunization Have rash , dermatological condition , tattoo , muscle mass injection site may interfere injection site reaction rating Have receive blood transfusion within 90 day prior study vaccination If female , positive pregnancy test result screening , prior immunization Day 0 Day 21 Female subject lactate Any vital sign abnormality : systolic blood pressure , diastolic blood pressure , rest heart rate well control accord Investigator 's opinion Cancer treatment cancer within 3 year study vaccine administration . Persons history cancer diseasefree without treatment 3 year eligible . Persons treat uncomplicated basal cell carcinoma skin eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Influenza , Human</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Respiratory Tract Infections</keyword>
	<keyword>Aluminum Hydroxide</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Immunogenic Factors</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Infection</keyword>
</DOC>